While baseline percentages of circulating Vγ9Vδ2 T cells were not significantly correlated to any of the well established prognostic factors for melanoma (stage, RFS and OS), progression was invariably associated to substantial declines in Vγ9Vδ2 T cell numbers, reminiscent of our previous observations after Zoledronate and IL-2 injection in cancer patients. This evidence concerns the gene IL2 and cancer.